MK-677 (Ibutamoren): What the Evidence Actually Shows

MK-677 — chemical name ibutamoren mesylate — is not a peptide, despite being discussed constantly alongside ones like sermorelin and ipamorelin. It's an orally active, non-peptide small molecule that happens to agonize the same ghrelin receptor (GHS-R1a) ipamorelin targets through a completely different, structurally unrelated pentapeptide. That distinction is the load-bearing fact behind everything else about this compound: because it's a small molecule rather than a peptide chain, it survives oral dosing — no injection, no reconstitution — where a true peptide typically wouldn't.

What the real 2-year human trial actually found

The strongest evidence on MK-677 comes from a genuinely rigorous trial: a 2-year, double-blind, placebo-controlled, modified-crossover RCT in 65 healthy adults aged 60-81, given oral MK-677 25mg/day or placebo¹. It did what it's mechanistically supposed to do — GH and IGF-I rose into the young-adult range without serious adverse effects reported at that level¹. Fat-free mass increased in the MK-677 group while it declined in the placebo group (P<.001)¹. But several findings worth stating precisely rather than rounding into a blanket "it works": abdominal visceral fat and total fat mass showed no significant difference between groups¹ — the fat-free-mass gain did not come with fat loss. Fasting blood glucose rose an average of 0.3 mmol/L (5 mg/dL, P=.015) and insulin sensitivity decreased¹. And despite the real fat-free-mass increase, the trial found no corresponding improvement in strength or function¹ — more lean tissue, not more capability, at least not over this trial's duration. The most frequent side effects were a temporary increase in appetite and mild, transient lower-extremity edema and muscle pain¹.

A second trial, stopped early over a cardiac signal

A separate, 123-patient, multicenter RCT tested MK-677 (branded MK-0677 in this trial) for functional recovery after hip fracture, at the same 25mg/day dose². IGF-I rose significantly, as expected, and gait speed improved — but most other functional performance measures showed no improvement². The trial's own conclusion is direct: it was TERMINATED EARLY due to a safety signal of congestive heart failure in a limited number of patients², concluding that "MK-0677 has an unfavorable safety profile in this [elderly, hip-fracture] patient population²." A broader 2018 review of growth-hormone secretagogues corroborates the same underlying concern independently — available studies show GHSs are generally well tolerated, but "with some concern for increases in blood glucose because of decreases in insulin sensitivity³," the same signal the Nass trial found directly.

No FDA-approved human product — confirmed at the label level, not just by absence

A live DailyMed search for "ibutamoren" returns exactly two results, and reading the actual structured-product-label data rather than trusting the search-result titles matters here: both are titled "(IBUTAMOREN MESYLATE) POWDER" from AX Pharmaceutical Corp, and their own coded product type is "bulk ingredient for animal drug compounding" — not a human drug product of any kind. FDA's current 503A Bulks List, updated May 14, 2026 and re-fetched live for this article, lists Ibutamoren Mesylate under Category 2 — "Bulk Drug Substances that Raise Significant Safety Risks" — the same category as cesium chloride and domperidone, and a meaningfully more serious regulatory posture than most GH-axis peptides this site covers, most of which simply aren't on FDA's active-review radar at all.

The FAERS record

A live openFDA FAERS check for ibutamoren returns 12 total adverse-event reports, with cerebrovascular accident (3), cold-type haemolytic anaemia (2), jaundice (2), liver injury (2), off-label use (2), and seizure (2) among the most frequent reaction terms. Twelve reports is too small a sample to compute a real incidence rate from, but the reaction-term list is worth reading alongside the two trial findings above rather than dismissing outright — it's directionally consistent with a compound flagged for cardiac and metabolic safety signals in its own controlled trial data, not an unrelated pattern.

What this means if you're considering it

MK-677 has real, rigorous human trial data behind it — more than many peptides this site covers — and that data cuts both ways. It genuinely raises GH and IGF-I to young-adult levels and increases fat-free mass; it also raises fasting glucose, reduces insulin sensitivity, and was linked to a heart-failure signal serious enough to stop a separate trial early. FDA's own compounding reviewers list it in their significant-safety-risk category, a stricter posture than sermorelin, CJC-1295, or ipamorelin currently carry. If you're weighing it specifically against sermorelin, our direct MK-677 vs. sermorelin comparison covers that head-to-head, including the boarded provider landscape. There's no MK-677 reconstitution calculator on this site because there's nothing to reconstitute — it's an oral capsule or powder, not an injectable.